Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers
- 1 December 2022
- journal article
- research article
- Published by Mary Ann Liebert Inc in Population Health Management
- Vol. 25 (6), 753-762
- https://doi.org/10.1089/pop.2022.0075
Abstract
Rising prescription costs, poor medication adherence, and safety issues pose persistent challenges to employer-sponsored health care plans and their beneficiaries. Comprehensive medication management (CMM), a patient-centered approach to medication optimization, enriched by pharmacogenomics (PGx), has been shown to improve the efficacy and safety of pharmaceutical regimens. This has contributed to improved health care outcomes, reduced costs of treatments, better adherence, shorter durations of treatment, and fewer adverse effects from drug therapy. Despite compelling clinical and economic evidence to justify the application of CMM guided by PGx, implementation in clinical settings remains sparse; notable barriers include limited physician adoption and health insurance coverage. Ultimately, these challenges may be overcome through comprehensive programs that include clinical decision support systems and education through employer-sponsored population health management channels to the benefit of the employees, employers, health care providers, and health care systems. This article discusses benefits, considerations, and barriers of scalable PGx-enriched CMM programs in the context of self-insured employers.Keywords
This publication has 83 references indexed in Scilit:
- Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing InformationJournal of Personalized Medicine, 2013
- Cost of a Group Translation of the Diabetes Prevention Program: Healthy Living Partnerships to Prevent DiabetesAmerican Journal of Preventive Medicine, 2013
- Insurance Coverage Policies for Personalized MedicineJournal of Personalized Medicine, 2012
- Primary care physicians' knowledge of and experience with pharmacogenetic testingClinical Genetics, 2012
- A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)Circulation, 2012
- Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary FindingsGenetic Testing and Molecular Biomarkers, 2012
- Survey of US public attitudes toward pharmacogenetic testingThe Pharmacogenomics Journal, 2011
- Assessing Patient Readiness for the Clinical Adoption of Personalized MedicinePublic Health Genomics, 2009
- What Are the Implications of the STAR*D Trial for Primary Care?The Primary Care Companion For CNS Disorders, 2008
- The cost‐effectiveness of a smoking cessation program for out‐patients in treatment for depressionAddiction, 2008